The most common ICIs were pembrolizumab (29/44, 66%) and nivolumab (12/44, 27%)....Among pts with LRP1b PVs, 36% (95%CI 14%-64%) had radiographic responses (5/14, 2 lung, 1 prostate, 1 RCC, 1 endometrial carcinoma), two of whom were MSI high....The majority of responders were MSS and TMB low, which may suggest that PV in LRP1B may independently predict for response to ICI.

...the prevalence of LRP1b mutations in our cohort was 22% (4/18), and the response to pembrolizumab (PSA decline ≥50%) in this genomic subset was 75%...with duration of response ranging from 4.6 to 16.3 months. Among men with genomic profiling not revealing mutations in LRP1b, the response to pembrolizumab (PSA decline ≥50%) was 14% (2/14), with duration of response ranging from 0.7 to 4.2 months.